Shares of Oxford BioMedica plc (LON:OXB) hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 11.54 ($0.16) and last traded at GBX 10.94 ($0.15), with a volume of 23000000 shares trading hands. The stock had previously closed at GBX 10.94 ($0.15).
Separately, Peel Hunt began coverage on shares of Oxford BioMedica in a research note on Tuesday, September 19th. They set a “buy” rating and a GBX 13 ($0.18) price target on the stock.
In other Oxford BioMedica news, insider Lorenzo Tallarigo purchased 30,861 shares of the company’s stock in a transaction that occurred on Thursday, November 23rd. The shares were bought at an average cost of GBX 9 ($0.12) per share, for a total transaction of £2,777.49 ($3,766.60). Insiders have purchased a total of 90,662 shares of company stock worth $815,958 over the last 90 days.
COPYRIGHT VIOLATION WARNING: This article was posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/markets/oxford-biomedica-oxb-reaches-new-52-week-high-at-11-54/1824152.html.
About Oxford BioMedica
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with our FREE daily email newsletter.